Gilead Appoints SVP of Research Biology

Gilead Appoints Michael Quigley to Lead Research Biology Group

FOSTER CITY, Calif.–(BUSINESS WIRE)–Feb. 19, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) announced that Michael Quigley, PhD has joined the company as Senior Vice President, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology.

Dr. Quigley joins Gilead from Bristol-Myers Squibb, where most recently he was Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center and Site Head of the Redwood City, California location. In that role, Dr. Quigley was responsible for setting strategy for Bristol-Myers Squibb’s oncology discovery portfolio and business development activities, overseeing target identification, validation and preclinical development of large and small molecule therapies.

He received a PhD in Immunology from Duke University and conducted his post-doctoral research at the Dana Farber Cancer Institute, Department of Pediatric Oncology. Dr. Quigley will report to William Lee, PhD, Executive Vice President of Research.

The company also announced that Linda Higgins, PhD, has recently taken on the role of Senior Vice President and Head of External Innovation. Dr. Higgins joined Gilead in 2010, leading a significant expansion of the company’s Biology organization that included the establishment of Biologics and Biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.

“We are very pleased to welcome Mike to Gilead and Linda to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” commented Dr. Lee. “These appointments strengthen our research discovery organization and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”

ON Partners and partner Suzanne Zebedee are proud to have partnered with Gilead and Dr. Quigley on this successful placement.

Read the full press release.  Dr. Quigley’s appointment is also featured in the online publication pharmaphorum.

ABOUT GILEAD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.  For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

ABOUT ON PARTNERS

ON Partners propels an organization’s mission by building C-level and board leadership teams. Founded in 2006 by like-minded consultants as a values-driven alternative to the multi-service global firms they were leaving behind, ON delivers a better executive search experience. The firm has been named to the Inc. 500/5000 Lists six times, was named to the Inc. 5000 Hall of Fame in 2018 and is consistently ranked among the top 20 retained executive search firms in the U.S. For more information on our Life Science practice, see our results here.

Follow our work, updates and recent success on Twitter and LinkedIn.

Find our related successful placements of leading executives here.